acetylgalactosamine has been researched along with heme in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KE; Ávila, MA; Deybach, JC; Fontanellas, A | 1 |
| de Paula Brandão, PR; Titze-de-Almeida, R; Titze-de-Almeida, SS | 1 |
| Aarsand, AK; Aguilera, P; Brunet, M; Deulofeu, R; García-Villoria, J; Gómez-Gómez, À; Pozo, OJ; Sandberg, S; To-Figueras, J; Wijngaard, R | 1 |
| Beykirch, MK; Klein, M; Loehr, C; Molitor, B; Obermeier, Z; Petrides, PE; Schuhmann, E; Torkler, H | 1 |
| Bouchoule, I; Cerutti, D; Douillard, C; Duchêne, F; Dupré, T; Faivre, A; Fiorentino, V; Gouya, L; Grobost, V; Lefebvre, T; Manceau, H; Mirmiran, A; Moulouel, B; Peoc'h, K; Poli, A; Puy, H; Rivière, S; Schmitt, C; Talbi, N | 1 |
| Harper, P; Sardh, E | 1 |
3 review(s) available for acetylgalactosamine and heme
| Article | Year |
|---|---|
Current and innovative emerging therapies for porphyrias with hepatic involvement.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; alpha-MSH; Bone Marrow Transplantation; Cholestyramine Resin; Genetic Therapy; Heme; Humans; Liver; Liver Transplantation; Porphyrias, Hepatic; Porphyrins; Pyrrolidines; Receptor, Melanocortin, Type 1 | 2019 |
Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
Topics: Acetylgalactosamine; Clinical Trials as Topic; Drug Development; Gene Silencing; Genetic Therapy; Heme; Humans; Nitric Oxide Synthase Type I; Porphyria, Acute Intermittent; Pyrrolidines; RNA Interference; RNA, Small Interfering; Treatment Outcome | 2020 |
RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Topics: Acetylgalactosamine; Adolescent; Adult; Heme; Humans; Incidence; Porphobilinogen Synthase; Porphyria, Acute Intermittent; Porphyrias, Hepatic; Pyrrolidines; Quality of Life; RNAi Therapeutics | 2022 |
3 other study(ies) available for acetylgalactosamine and heme
| Article | Year |
|---|---|
Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
Topics: Acetylgalactosamine; Adult; Arginine; Cystathionine beta-Synthase; Female; Folic Acid; Heme; Homeostasis; Homocysteine; Homocystinuria; Humans; Hydroxymethylbilane Synthase; Hyperhomocysteinemia; Male; Methionine; Middle Aged; Porphyria, Acute Intermittent; Pyridoxal Phosphate; Pyrrolidines; Young Adult | 2021 |
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Adult; Arginine; Colitis; Colon, Sigmoid; Controlled Clinical Trials as Topic; Drug Hypersensitivity; Female; Fibrosis; Heme; Hepatocytes; High-Throughput Nucleotide Sequencing; Homocysteine; Humans; Hydroxymethylbilane Synthase; Hyperhomocysteinemia; Male; Models, Biological; Pancreatitis; Porphyria, Acute Intermittent; Pyrrolidines | 2021 |
Givosiran in acute intermittent porphyria: A personalized medicine approach.
Topics: Acetylgalactosamine; Acute Disease; Heme; Humans; Pancreatitis; Porphyria, Acute Intermittent; Precision Medicine; Pyrrolidines; Retrospective Studies | 2022 |